Literature DB >> 24717015

The current relevance and use of prednisone in rheumatoid arthritis.

Marco Krasselt1, Christoph Baerwald.   

Abstract

Prednisone is an old and very valuable drug in clinical use for over 60 years by now. It is well known by physicians and widely used for different kinds of inflammatory states including rheumatoid arthritis (RA). Clinical trials during the last 20 years have changed its clinical use, particularly with regards to dosage. Today, rheumatologists are treating their patients much more likely over a long period of time using a low-dose scheme. The effectiveness and safety of this low-dose use is the objective of the current clinical research and shall be enlightened in this drug profile. It is also featuring current knowledge about the value of modified-release prednisone with regards to the just published results of the 2nd Circadian Administration of Prednisone in Rheumatoid Arthritis trial. Moreover, the mechanisms of action of prednisone and its relatives will be summed up.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24717015     DOI: 10.1586/1744666X.2014.904746

Source DB:  PubMed          Journal:  Expert Rev Clin Immunol        ISSN: 1744-666X            Impact factor:   4.473


  14 in total

1.  [S3 guidelines on long-term opioid treatment in non-cancer pain. Recommendations for opioid use in clinical rheumatology].

Authors:  M Krasselt; W Häuser; F Petzke; C Baerwald
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

2.  Low vaccination rates among patients with rheumatoid arthritis in a German outpatient clinic.

Authors:  Marco Krasselt; Jean-Philipp Ivanov; Christoph Baerwald; Olga Seifert
Journal:  Rheumatol Int       Date:  2016-11-22       Impact factor: 2.631

3.  Insufficient vaccination rates in patients with systemic lupus erythematosus in a German outpatient clinic.

Authors:  M Krasselt; C Baerwald; O Seifert
Journal:  Z Rheumatol       Date:  2018-10       Impact factor: 1.372

4.  Targeted delivery of hyaluronic acid-coated solid lipid nanoparticles for rheumatoid arthritis therapy.

Authors:  Meiling Zhou; Jierong Hou; Zhirong Zhong; Na Hao; Yan Lin; Chunhong Li
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

Review 5.  Types of pain and their psychosocial impact in women with rheumatoid arthritis.

Authors:  Maria Gabriela Chancay; Shirin Nouri Guendsechadze; Irene Blanco
Journal:  Womens Midlife Health       Date:  2019-08-09

Review 6.  The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions.

Authors:  Shahin Shams; Joseph M Martinez; John R D Dawson; Juan Flores; Marina Gabriel; Gustavo Garcia; Amanda Guevara; Kaitlin Murray; Noah Pacifici; Maxemiliano V Vargas; Taylor Voelker; Johannes W Hell; Judith F Ashouri
Journal:  Front Pharmacol       Date:  2021-05-28       Impact factor: 5.810

7.  Mortality of Sepsis in Patients With Rheumatoid Arthritis: A Single-Center Retrospective Analysis and Comparison With a Control Group.

Authors:  Marco Krasselt; Christoph Baerwald; Sirak Petros; Olga Seifert
Journal:  J Intensive Care Med       Date:  2020-04-06       Impact factor: 3.510

8.  Safety and pharmacodynamic dose response of short-term prednisone in healthy adult subjects: a dose ranging, randomized, placebo-controlled, crossover study.

Authors:  Dona L Fleishaker; Arnab Mukherjee; Fredrick S Whaley; Shanthini Daniel; Bernhardt G Zeiher
Journal:  BMC Musculoskelet Disord       Date:  2016-07-16       Impact factor: 2.362

Review 9.  Efficacy and safety of modified-release prednisone in patients with rheumatoid arthritis.

Authors:  Marco Krasselt; Christoph Baerwald
Journal:  Drug Des Devel Ther       Date:  2016-03-08       Impact factor: 4.162

10.  Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial.

Authors:  Matthijs S van der Leeuw; Paco M J Welsing; Maria J H de Hair; Johannes W G Jacobs; Anne C A Marijnissen; Suzanne P Linn-Rasker; Faouzia Fodili; Reinhard Bos; Janneke Tekstra; Jacob M van Laar
Journal:  Trials       Date:  2020-04-05       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.